Clinical trial · Expanded Access
Expanded Access:18F-Fluorocholine for the Detection of Parathyroid Adenomas
NCT07218224CI-TRIAL-00096674availableClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This expanded access protocol is proposed to allow University of California San Francisco (UCSF) patients additional access to 18F-fluorocholine (FCH) Positron Emission Tomography (PET) imaging for localization of parathyroid adenomas.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Parathyroid Adenomas | Parathyroid Gland Neoplasm | ALIAS | 0.90 |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| 18F-Fluorocholine (FCH) | Drug | — | UNRESOLVED |
| Positron emission tomography (PET) | Procedure | — | UNRESOLVED |
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 13 Years
Show eligibility criteria text
Inclusion Criteria: 1. Age ≥ 13 years. 2. Evidence of primary hyperparathyroidism. 3. Ability to understand a written informed consent document, and the willingness to sign it. Exclusion Criteria: 1\. Unlikely to comply with protocol procedures, restrictions and requirements and judged by the Investigator to be unsuitable for participation.
References
Publications (0)
Data not yet available
No reference posted for this study.